Calcipotriene Blog

Stiefel, a GSK company, Receives FDA Approval of Sorilux (calcipotriene) Foam, 0.005%

Posted 18 Oct 2010 by Drugs.com

Research Triangle Park, N.C. – October 12, 2010 – Stiefel, a GSK company, today announced that the U.S. Food and Drug Administration (FDA) has approved Sorilux (calcipotriene) Foam, 0.005%, for the topical treatment of plaque psoriasis in patients aged 18 years and older. Stiefel received the approval approximately two weeks in advance of the anticipated FDA action date. Plaque psoriasis is a chronic, non-contagious, inflammatory skin condition that appears as red patches covered with silvery flakes often found on the elbows, scalp and knees but can also affect other parts of the body. "Plaque psoriasis affects up to six million Americans each year," said Bill Humphries, president, Stiefel, "Which is why Stiefel is so committed to bringing new therapy options, like Sorilux Foam, to patients." Sorilux Foam was found to be effective in treating mild to moderate plaque psoriasis. It con ... Read more

Related support groups: Psoriasis, Calcipotriene